Alternative complement pathway activation during invasive coronary procedures in acute myocardial infarction and

Zsófia Horváth1, Dorottya Csuka2, Katarina Vargova3

  • 1Research Group for Inflammation Biology and Immunogenomics of Hungarian Academy of Sciences and Semmelweis University, Róbert Károly krt. 44, 1134 Budapest, Hungary; Hungarian Defence Forces Medical Centre, Department of Cardiology, Róbert Károly krt. 44, 1134 Budapest, Hungary.

Insights

Percutaneous coronary procedures activate the alternative complement pathway, especially with contrast dye. In ST-elevation myocardial infarction, this pathway is already active before procedures.

Area of Science:

  • Cardiovascular Medicine
  • Immunology
  • Interventional Cardiology

Background:

  • The impact of percutaneous coronary procedures on complement activation remains unclear.
  • Complement system activation is implicated in inflammatory responses and tissue injury.

Purpose of the Study:

  • To investigate the effect of elective percutaneous coronary intervention (PCI) and diagnostic coronary angiography (CA) on complement activation.
  • To compare complement activation in stable angina patients undergoing elective PCI (SA-PCI) versus ST-segment elevation myocardial infarction patients undergoing primary PCI (STEMI-PCI).

Main Methods:

  • Measurement of complement activation products (C1rC1sC1inh, C3bBbP, SC5b-9) in SA-PCI (n=24), CA (n=52), and STEMI-PCI (n=23) patients.
  • Blood samples collected at baseline, 6 hours, and 24 hours post-procedure.
  • Correlation analysis between complement levels and clinical parameters (CK, creatinine, contrast volume).

Main Results:

  • Elective PCI and CA induced a significant, reversible increase in the alternative pathway product C3bBbP 6 hours post-procedure (p<0.01).
  • C3bBbP levels at 6 hours correlated with post-procedural CK, creatinine, and contrast volume.
  • STEMI-PCI patients exhibited higher baseline C3bBbP and SC5b-9 levels compared to SA-PCI and CA patients (p<0.001 and p=0.011, respectively).
  • Primary PCI in STEMI patients did not lead to further complement activation.

Conclusions:

  • Elective coronary procedures trigger transient alternative complement pathway activation, influenced by contrast material volume.
  • In STEMI, the alternative complement pathway is activated by the acute atherothrombotic event, with PCI having no additional detectable effect.

Related Concept Videos

Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
1.4K
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
611
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
374
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
362
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
358
Angina II: Classification01:27

Angina II: Classification

Angina, also known as angina pectoris, is a chest pain resulting from diminished blood flow to the heart muscle and is often a symptom of coronary artery disease. Angina presents several variants with distinctive attributes, etiologies, and therapeutic approaches. The main types of angina include stable, unstable, variant (Prinzmetal's), microvascular, intractable, and silent ischemia.Stable angina is caused by atherosclerosis, which leads to the formation of plaques that narrow the coronary...
515